Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.37 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.37 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.37 |
| ▸ | GAPDH | P04406 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | STAT6 | P42226 | 1/20 | 0.37 |
| ▸ | PI4KA | P42356 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2584222 | 0.87 | ADORA1 (0.37) | SMN1; SMN2ALDH1A1HTTBLMKDM4E | |
| SCHEMBL2579342 | 0.86 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1HTTBLMKDM4E | |
| SCHEMBL2584026 | 0.85 | ADK (0.36) | SLC28A2LMNATP53HPGD | |
| SCHEMBL2578109 | 0.81 | SLC29A1 (0.53) | SMN1; SMN2ALDH1A1HTTBLMADORA3 | |
| SCHEMBL6886934 | 0.80 | SLC29A1 (0.51) | SMN1; SMN2ADORA3DPP4MEN1SLC28A1 | |
| SCHEMBL2584815 | 0.80 | HSPA5 (0.37) | ALDH1A1HTTBLMKDM4ESLC28A2 | |
| SCHEMBL2587219 | 0.79 | HSPA8 (0.34) | SLC28A2SLC29A1 | |
| SCHEMBL2579190 | 0.78 | LMNA (0.51) | SMN1; SMN2ALDH1A1LMNATP53 | |
| SCHEMBL6885472 | 0.75 | SLC29A1 (0.52) | SMN1; SMN2ADORA3DPP4MEN1SLC28A1 | |
| SCHEMBL6889026 | 0.75 | LMNA (0.69) | ALDH1A1ADORA3MEN1MAPK1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10100076-B2 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | GILEAD PHARMASSET LLC (US) | 2018-10-16 | — | — | US | disclosed |
| US-20140057863-A1 | MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | GILEAD SCIENCES, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| EP-2251015-B1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | GILEAD PHARMASSET LLC (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20110269707-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation | PHARMASSET, INC. | 2011-11-03 | — | — | US | disclosed |
| EP-2251015-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | Pharmasset, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | PHARMASSET, INC. | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057863-A1 | MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | SLC29A1, PNP, SLC29A2 | SMN1; SMN2 214/4885ALDH1A1 1466/4885HTT 4480/4885 |
| US-20110269707-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation | PNP, ALPP, XDH | SMN1; SMN2 676/4885ALDH1A1 2416/4885HTT 4766/4885 |
| US-10100076-B2 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | SLC29A1, SLC29A2, PNP | SMN1; SMN2 63/4885ALDH1A1 1128/4885HTT 4514/4885 |
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | SLC29A1, PNP, SLC29A2 | SMN1; SMN2 244/4885ALDH1A1 1367/4885HTT 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.